Intravitreal Injectables Market Segmented By Macular Degeneration, Diabetic Retinopathy, Retinal Vein Occlusion, Endophthalmitis Indication in Anti-VEGF, Corticosteroids, Antibiotics, Antivirals, Antifungals Drug Class
Report ID: PMRREP25906
Number of Pages: 276
Format: PPT*, PDF, EXCEL
Industry: Healthcare
Published Date: May-2022
Intravitreal injection is a safe and efficient therapeutic option for retinal diseases such as diabetic retinopathy, macular degeneration, endophthalmitis, retinal vein occlusion, and others. Growing retinal problems are likely to drive the global intravitreal injectable market at a rapid pace throughout the forecast period. The Global Intravitreal (IVT) Injectable Market is estimated to reach $23,814.3 million by 2028, having a CAGR of 4.9%.
| Attribute | Key Insights |
|---|---|
|
Intravitreal (IVT) Injectable Market Size (2022) |
US$ 17,849.5 Mn |
|
Projected Market Value (2028) |
US$ 23,814.3 Mn |
|
Global Market Growth Rate (2022 - 2028) |
4.9% CAGR |
|
Share in parent market |
7.4% |
Report Sample is Available
In-depth report coverage is now just a few seconds away
Get Report Sample
The vitreo-retinal disease has been a significant reason for blindness and visual impairment all over the world. Many people suffer from retinal problems, which frequently result in vision loss or total blindness. Intravitreal injection is a secure and convenient treatment option for retinal diseases such as diabetic retinopathy, macular degeneration, endophthalmitis, retinal vein occlusion, and others. Growing retinal problems are likely to drive the global intravitreal injectable market at a significant rate throughout the forecast period.
Make This Report Your Own
Take Advantage of Intelligence Tailored to your Business Objective
Get a Customized VersionThe vitreo-retinal disease has been the main reason for visual impairment and blindness all over the world. Intravitreal (IVT) injectables are an important part of the therapy of retinal diseases. Patients with chronic retinal illnesses require recurring intravitreal (IVT) injectable doses, and hence the intravitreal (IVT) injectables market is expected to grow substantially over the projected period.
Many pharmaceutical companies are concentrating on developing novel medications to treat intraocular disorders and address patients' unmet requirements. Several market players are working on treatments for various purposes that will most likely be delivered via intravitreal (IVT) injectables.
Intravitreal (IVT) Injectables are becoming increasingly popular among doctors since these are more effective and safer than the other therapy alternatives for intraocular diseases. Intravitreal (IVT) injectables are utilized to treat a wide range of retinal disorders. It could be utilized to administer anticancer, antivascular endothelial growth factor, anti-inflammatory, antibacterial, surgical gases, and the other medicinal substances. Intravitreal (IVT) injectables efficiently cure retinal problems and are being widely utilized for treatments of intraocular diseases, hence the increasing demand for Intravitreal (IVT) Injectables market is expected to rise rapidly in the near future.
Anti-VEGF therapies are generally used to treat chronic retinal illnesses such as diabetic retinopathy, macular degeneration, retinal vein occlusion, and others. The increasing frequency of these severe conditions has led to an increase in the adoption of anti-VEGF therapies, which result in a significant need for intravitreal (IVT) injectables. The increasing adoption of anti-VEGF will fuel market growth going forward.
“Risks and Complications Associated with Intravitreal (IVT) Injectables”
Intravitreal (IVT) Injectables are becoming increasingly popular among doctors because they are safer and more effective. However, the necessity of repeated intravitreal injections, as well as the risks or problems associated with injectables, such as infection and inflammation in the eye, retinal detachment, and vitreous hemorrhage, are expected to restrain the global market in the future.
“Reduction in Clinic Visits and Intravitreal (IVT) Injectables”
The global economy has been damaged by the Covid-19 pandemic. Due to lockdowns and an overwhelming number of covid-19 patients, attendance at scheduled clinic appointments and Intravitreal (IVT) Injectables had decreased. However, the situation improved when the covid-19 restrictions were lifted in September 2021, and demand for intravitreal (IVT) injectables increased once again.
The Intravitreal (IVT) Injectable Market is highly competitive, with the presence of global giants. To expand their product portfolio footprint in the intravitreal injectables market, prominent players are implementing organic and inorganic methods such as product launches, collaboration, product agreements, etc.
| Attribute | Details |
|---|---|
|
Forecast Period |
2022 - 2028 |
|
Historical Data Available for |
2013-2021 |
|
Market Analysis |
US$ Mn/Bn for Value |
|
Key Regions Covered |
|
|
Key Countries Covered |
|
|
Key Market Segments Covered |
By Indication |
|
Key Companies Profiled |
|
|
Customization & Pricing |
Available upon Request |
Intravitreal (IVT) Injectable Market by Indication
Intravitreal (IVT) Injectable Market by Drug Class
Intravitreal (IVT) Injectable Market by Region
For report customisation and delivery information contact our sales representative.
In 2022, the Intravitreal (IVT) Injectable Market stands at USD 17,849.5 million, and it is expected to reach USD 23,814.3 million by 2028 at a CAGR of 4.9%.
Intravitreal (IVT) Injectable Market exhibited a CAGR of 4.4% between 2013 and 2021.
Risks and complications associated with Intravitreal (IVT) Injectables are the key restraints in the Intravitreal (IVT) Injectable Market.
Increasing prevalence Of Retinal Diseases and the increased demand for Intravitreal (IVT) Injectables are the key factors driving the growth of the market.
Regeneron Pharmaceuticals Inc., Bausch & Lomb, Novartis AG, and Allergan are among the top players in the market.
